Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inulin-adjuvanted seasonal trivalent inactivated influenza vaccine
- Development stage
- Unknown
- Lead developer
- Vaxine
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The inulin-adjuvanted seasonal trivalent inactivated influenza vaccine is a clinical-stage biologic developed by Vaxine Pty Ltd. It consists of a standard seasonal trivalent inactivated influenza vaccine (TIV) formulated with Advax, a novel polysaccharide adjuvant derived from delta inulin. The Advax adjuvant is designed to enhance and accelerate humoral immune responses, including B cell affinity maturation and plasmablast generation, without inducing excessive inflammation. This vaccine targets seasonal influenza strains, specifically H1N1, H3N2, and Influenza B. Clinical development has focused on assessing safety, immunogenicity, and the potential for antigen-sparing formulations in healthy adults.
- Brand names
- Advax
- Other names
- Advax-adjuvanted trivalent inactivated influenza vaccineAdvax-adjuvanted TIVinulin-adjuvanted TIV
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on inulin-adjuvanted seasonal trivalent inactivated influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inulin-adjuvanted seasonal trivalent inactivated influenza vaccine.